Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwCLL 2019 | Signal-omics to fingerprint the impact of antigen engagement in CLL

Adam Linley • 22 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia

Adam Linley, PhD, University of Liverpool, Liverpool, UK, gives us an overview of his study of signal-omics to fingerprint the impact of antigen engagement and therapy on BCR activation in chronic lymphocytic leukemia (CLL). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Adam Linley

CLL: modelling functional differences between sIgM, sIgD and chemokine signalling 0:44
CLL: modelling functional differences between sIgM, sIgD and chemokine signalling
Adam Linley • 22 Sep 2019

Related Videos

The safety and efficacy of rapcabtagene autoleucel in adult patients with R/R B-ALL 1:41
The safety and efficacy of rapcabtagene autoleucel in adult patients with R/R B-ALL
Pere Barba • 7 Dec 2025
Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia 1:48
Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia
Michael Savona • 6 Dec 2025
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML 1:31
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML
Wei-Ying Jen • 6 Dec 2025
The development and international validation of an unsupervised classification model in AML 1:28
The development and international validation of an unsupervised classification model in AML
Amin Turki • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals